Observational Study of Patients With Mucopolysaccharidosis (MPS) VI Who Previously Participated in ASB-00-02

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

59 participants

Study Classification

OBSERVATIONAL

Study Start Date

2011-06-30

Study Completion Date

2013-02-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

There is limited information on the long-term effects of treating patients with MPS VI with Naglazyme® and limited data on the natural history of treated and untreated MPS VI patients. The Re-survey Study ASB-00-03 will assist in understanding the effects of long-term Naglazyme treatment and the natural history of the MPS VI patient population.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Phase 4 Two Dose Level Study of Naglazyme(TM) (Galsulfase) in Infants With MPS VI

NCT00299000

Mucopolysaccharidosis VI Maroteaux-Lamy Syndrome

COMPLETED PHASE4

Mucopolysaccharidosis (MPS) VI Clinical Surveillance Program (CSP)

NCT00214773

Mucopolysaccharidosis VI (MPS VI, Maroteaux-Lamy Syndrome)

COMPLETED

Study of rhASB in Patients With Mucopolysaccharidosis VI

NCT00104234

Mucopolysaccharidosis VI

COMPLETED PHASE3

A Open Label Study in Previously Studied, SBC-103 Treatment Naïve MPS IIIB Subjects to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics/Efficacy of SBC-103 Administered Intravenously

NCT02618512

Mucopolysaccharidosis III, Type B (MPS IIIB) Sanfilippo B

TERMINATED PHASE1/PHASE2

Open-Label Study of Efficacy and Safety of Recombinant Human N-acetylgalactosamine 4-sulfatase in Patients With MPS VI

NCT00048711

Mucopolysaccharidosis VI

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

MPS VI

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Willing and able to provide written, signed informed consent, or in the case of patients under the age of 16 years, provide written assent (if required) and written informed consent by a legally authorized representative after the nature of the study has been explained, and prior to any research-related procedures.
* Previously participated in Survey Study ASB-00-02, and met the criteria of a MPS VI diagnosis.
* Willing to perform all study assessments and procedures as physically possible.

Exclusion Criteria

* Concurrent disease or condition that would interfere with study participation or safety.
* Any condition that, in the view of the Investigator would place the patient at high risk of not completing the study.
* Concurrent enrollment and randomization into a clinical study of MPS VI treatment. Patients enrolled in the BioMarin MPS VI Clinical Surveillance Program may be enrolled in the Re-survey Study ASB-00-03.

Eligible Sex

ALL

Accepts Healthy Volunteers

No